Diabetic Nephropathy — How Diabetes Damages the Kidneys and How to Slow It
India has more than 77 million people living with diabetes the second-largest diabetic population in the world. Of those, approximately 40% will develop some degree of diabetic kidney disease (diabetic nephropathy) during the course of their illness. In Telangana and Andhra Pradesh, where type 2 diabetes prevalence is among the highest in the country, diabetic nephropathy is the single leading cause of chronic kidney disease and end-stage renal disease requiring dialysis or transplant. It is also, paradoxically, among the most preventable forms of advanced kidney disease if identified early and managed systematically.
The challenge is that diabetic nephropathy is silent in its early stages. The kidneys do not hurt. The urine looks normal to the naked eye. Blood creatinine the standard kidney test remains normal until 50 to 60% of kidney function has already been lost. The only reliable way to detect diabetic nephropathy at its earliest and most treatable stage is a urine test for microalbuminuria: a trace of protein leaking through the damaged kidney filter, detectable years before creatinine rises or symptoms appear. Most people with diabetes in India have never had this test.
This post explains how diabetes damages the kidneys, how to detect it early, how to stop or slow the damage, and what happens when diabetic nephropathy progresses to the point where kidney replacement therapy is needed. It is written for people with diabetes who want to protect their kidneys and for those who have already been told their kidneys are showing signs of diabetes-related damage.
How diabetes damages the kidneys
The kidney's filtering units the glomeruli are networks of tiny blood vessels (capillaries) that filter blood at high pressure. Each kidney contains approximately one million glomeruli. In diabetes, chronically elevated blood glucose levels cause a cascade of metabolic and structural changes in these capillaries:
Glomerular hyperfiltration
In the early years of diabetes, the glomeruli actually filter blood at an abnormally high rate — a compensatory response to the metabolic demands of high glucose. This hyperfiltration causes mechanical stress on the glomerular capillary wall and initiates progressive damage.
Glomerular basement membrane thickening
High glucose promotes the accumulation of advanced glycation end-products (AGEs) in the glomerular basement membrane — the filtering layer of the capillary wall. This thickening disrupts the normal selective filtration, allowing protein (specifically albumin) to leak through into the urine.
Mesangial expansion and nodular sclerosis
The mesangium — the structural matrix between glomerular capillaries — expands and eventually forms the Kimmelstiel-Wilson nodules that are pathognomonic of diabetic nephropathy on kidney biopsy. As the mesangium expands, it compresses the capillary loops and progressively reduces the number of functioning capillaries.
Interstitial fibrosis and tubular atrophy
Advanced diabetic nephropathy involves not just the glomeruli but the tubules and interstitium — progressive scarring that is largely irreversible and directly parallels the decline in eGFR.
Arteriolar changes
Hyaline arteriosclerosis of the afferent and efferent arterioles — particularly prominent in diabetic nephropathy — reduces blood flow to individual glomeruli, compounding glomerular damage.
The clinical consequence of this cascade is progressive loss of eGFR — tracked using the CKD staging system combined with progressive proteinuria. These two variables together are the primary determinants of how quickly diabetic nephropathy progresses to kidney failure.
Stages of diabetic nephropathy — from normal to kidney failure
| Stage | Details — eGFR · Urine findings · Clinical timeline · KIMS action |
|---|---|
| Stage 1 — Hyperfiltration | eGFR elevated (>120). Microalbuminuria may be absent. Timeline: within first 2–5 years of diabetes. Action: optimise glucose and BP control · annual ACR screening · SGLT2 inhibitor consideration. |
| Stage 2 — Microalbuminuria | eGFR normal (60–90). ACR 3–30 mg/mmol. Timeline: 5–15 years of diabetes. Action: ACE inhibitor or ARB · intensify HbA1c below 7% · SGLT2 inhibitor · annual nephrology review. |
| Stage 3 — Macroalbuminuria | eGFR 30–60. ACR above 30 mg/mmol. Timeline: 10–20+ years. Action: nephrology referral · SGLT2 inhibitor · finerenone consideration · dietary protein restriction · BP below 130/80 · fistula evaluation begins. |
| Stage 4 — Declining eGFR | eGFR 15–30. Heavy proteinuria. Advanced disease. Action: AV fistula creation · transplant evaluation · dialysis modality education · Aarogyasri registration. |
| Stage 5 — Kidney Failure | eGFR below 15. End-stage diabetic nephropathy. Action: haemodialysis or peritoneal dialysis initiation · transplant where eligible · 1,500+ transplants at KIMS. |
The microalbuminuria test — the most important kidney test a diabetic person can have
Microalbuminuria is the presence of albumin in the urine at concentrations that are too small to detect on a standard urine dipstick test but large enough to indicate early glomerular damage. The test used is the albumin-to-creatinine ratio (ACR) on a spot urine sample the result is expressed in mg/mmol or mg/g.
Normal ACR
Below 3 mg/mmol (30 mg/g)
Microalbuminuria (early diabetic nephropathy)
ACR 3–30 mg/mmol (30–300 mg/g)
Macroalbuminuria (established diabetic nephropathy)
ACR above 30 mg/mmol (300 mg/g)
Microalbuminuria is the earliest detectable marker of diabetic nephropathy appearing 5 to 10 years before the serum creatinine rises or eGFR falls. At the microalbuminuria stage, the kidney damage is still largely reversible with intensive glucose control, blood pressure control, and ACE inhibitor therapy. The combination of ACR testing and eGFR measurement annually in all diabetic patients is the international standard endorsed by KDIGO, ADA, and all major nephrology guidelines and it is the routine screen performed at every diabetic patient's annual nephrology review at KIMS.
Every person with type 2 diabetes should have their urine albumin-to-creatinine ratio (ACR) and eGFR checked at least once a year starting from the time of diabetes diagnosis. Every person with type 1 diabetes should have these tests annually from 5 years after diagnosis. If your diabetologist or GP has not requested these tests in the past 12 months, ask for them specifically. Finding microalbuminuria changes treatment finding it early can save your kidneys.
Treatment — how to slow diabetic nephropathy at every stage
Modern nephrology provides several powerful tools to slow or even halt the progression of kidney damage in diabetes. The standard of care involves a multi-pronged approach targeting glucose, blood pressure, and specific metabolic pathways.
Blood glucose control — HbA1c below 7%
The landmark UKPDS and DCCT studies established that intensive blood glucose control targeting HbA1c below 7% reduces the risk of developing microalbuminuria by 30 to 40% and slows progression from microalbuminuria to macroalbuminuria by a similar margin. For established diabetic nephropathy, the HbA1c target should be individualised aiming for below 7% in younger patients without hypoglycaemia risk, with higher targets (7.5 to 8%) acceptable in elderly patients or those with frequent hypoglycaemia. The KIMS nephrology team reviews HbA1c at every consultation and coordinates with the diabetologist when targets are not being achieved.
SGLT2 inhibitors — the most important advance in two decades
Sodium-glucose co-transporter 2 (SGLT2) inhibitors empagliflozin, dapagliflozin, canagliflozin were originally developed as glucose-lowering agents for type 2 diabetes. Their kidney-protective effects emerged unexpectedly in the cardiovascular outcome trials and were subsequently confirmed in dedicated kidney protection trials that changed nephrology practice globally. The DAPA-CKD trial (dapagliflozin, 2020) demonstrated a 44% relative risk reduction in kidney failure, death from kidney disease, or cardiovascular death in patients with CKD and proteinuria including non-diabetics. The CREDENCE trial (canagliflozin, 2019) showed a 34% reduction in the composite kidney endpoint in patients with diabetic nephropathy and eGFR 30 to 90. The EMPA-KIDNEY trial (empagliflozin, 2022) confirmed benefits across a broad range of CKD patients, including those with eGFR as low as 20. At KIMS, SGLT2 inhibitors are prescribed as part of the standard nephroprotective protocol for all diabetic CKD patients with eGFR above 20 and proteinuria — unless contraindicated. The team coordinates initiation with the diabetologist to monitor for adverse effects.
ACE inhibitors and ARBs the foundation of proteinuria reduction
ACE inhibitors (ramipril, enalapril, lisinopril) and ARBs (losartan, olmesartan, irbesartan) reduce proteinuria and slow diabetic nephropathy progression through mechanisms beyond blood pressure reduction they reduce intraglomerular pressure by dilating the efferent arteriole, directly reducing the mechanical stress on the glomerular capillary wall. The IRMA-2 and IDNT trials established ARBs as the first-choice agent for diabetic nephropathy with microalbuminuria or macroalbuminuria. The KIMS nephrology team uses ACE inhibitors or ARBs as the first antihypertensive choice in all diabetic CKD patients with proteinuria targeting both blood pressure below 130/80 and maximum tolerable proteinuria reduction.
Finerenone — the newest addition to the diabetic nephropathy protocol
Finerenone, a selective non-steroidal mineralocorticoid receptor antagonist, showed significant reduction in kidney failure progression in the FIDELIO-DKD and FIGARO-DKD trials in patients with diabetic nephropathy already on ACE inhibitor or ARB therapy. At KIMS, finerenone is considered in patients with persistent macroalbuminuria on maximal ACE inhibitor or ARB therapy and eGFR above 25, where the kidney failure risk remains high despite first-line treatment.
When diabetic nephropathy progresses to kidney failure — your options at KIMS
Despite best management, some patients with diabetic nephropathy progress to ESRD. For these patients, KIMS offers the complete spectrum of renal replacement therapy — with some important considerations specific to diabetic patients:
Haemodialysis in diabetics
Diabetic patients on haemodialysis have higher cardiovascular risk than non-diabetic ESRD patients — careful blood pressure management, lipid control, and cardiac monitoring are part of the KIMS dialysis programme. HDF (Haemodiafiltration) machines are available for long-term diabetic dialysis patients requiring superior middle molecule clearance.
Peritoneal dialysis for diabetics
PD is a particularly good option for many diabetic patients — the continuous gentle filtration avoids the haemodynamic stress of intermittent HD, cardiovascular pressure is lower, and residual kidney function is preserved longer. Glucose absorption from PD fluid must be managed carefully in diabetics. KIMS offers both CAPD and APD for diabetic ESRD patients.
Kidney transplant for diabetics
The definitive treatment. Typically 2 to 3 times better 5-year survival than dialysis. At KIMS, patients receive systematic workup for cardiovascular fitness and glycaemic control. Combined kidney-pancreas transplant is available for type 1 diabetics. For those with a living donor: begin evaluation at the same time as dialysis initiation. ABO-incompatible transplant removes the blood group barrier. Every year less on dialysis reduces the cardiovascular toll.
Frequently Asked Questions — Diabetic Nephropathy
Kidney damage in type 2 diabetes typically begins within the first 5 to 10 years of the disease — often before the diagnosis of diabetes is even made, since many people have had elevated blood glucose for years before formal diagnosis. Microalbuminuria — the earliest detectable marker of diabetic nephropathy — can appear as early as 5 years after type 2 diabetes diagnosis, and is present in 20 to 30% of patients with long-standing type 2 diabetes. In type 1 diabetes, the onset of nephropathy is typically 5 to 15 years after diagnosis. Annual ACR and eGFR testing from the time of diabetes diagnosis is the only way to identify nephropathy at its earliest and most treatable stage.
In the very early stages — microalbuminuria with normal eGFR — diabetic nephropathy can be partially reversed or stabilised with intensive glucose control, ACE inhibitor therapy, and SGLT2 inhibitor treatment. Studies have shown that microalbuminuria can regress to normal with optimal treatment. Once macroalbuminuria develops and eGFR begins to fall, true reversal is unlikely — but progression can be dramatically slowed, sometimes to the point of stability for years or even decades. The key is early detection and consistent treatment. Once eGFR falls below 30, the goal shifts from reversal to slowing progression and planning for renal replacement therapy.
The current evidence-based protocol for diabetic nephropathy with proteinuria combines: ACE inhibitor or ARB (first choice antihypertensive — reduces proteinuria independently of blood pressure) + SGLT2 inhibitor (dapagliflozin or empagliflozin — proven to reduce kidney failure events in the DAPA-CKD and EMPA-KIDNEY trials) + target HbA1c below 7% (or individualised target) + finerenone (in patients with persistent macroalbuminuria despite ACE inhibitor/ARB therapy). The combination of these four treatments represents the current standard of care and the KIMS nephrology protocol for diabetic CKD patients.
Every person with type 2 diabetes should have eGFR (from serum creatinine) and urinary ACR (albumin-to-creatinine ratio from a spot urine sample) checked annually — starting from the time of diabetes diagnosis. Every person with type 1 diabetes should have these tests annually from 5 years after diagnosis. If either test shows abnormality — eGFR below 60 or ACR above 3 mg/mmol — testing should be repeated at 3 to 6 monthly intervals and nephrology referral considered. At KIMS, these tests are routinely included in every diabetic patient's annual review.
Yes — diabetic patients are eligible for kidney transplant and benefit from it with the same survival advantage as non-diabetic ESRD patients. Diabetic patients may have higher cardiovascular risk at the time of transplant evaluation, requiring more thorough cardiac assessment (stress testing, coronary angiography where indicated). Post-transplant, immunosuppression medications — particularly tacrolimus and steroids — can worsen glycaemic control, requiring close coordination between the transplant nephrologist and diabetologist. At KIMS, diabetic transplant recipients are managed with a dedicated dual protocol — transplant immunosuppression and diabetic management — rather than treating each independently.
Yes — and this has been one of the most significant advances in nephrology in the past decade. The DAPA-CKD trial included a substantial proportion of patients with CKD and proteinuria who did not have diabetes, and dapagliflozin showed the same significant reduction in kidney failure events in non-diabetics as in diabetics. EMPA-KIDNEY confirmed benefits across a broad CKD population including non-diabetics. SGLT2 inhibitors are now standard of care for CKD with proteinuria regardless of diabetes status — the KIMS nephrology team uses them across the range of CKD indications where the evidence supports it.
Not necessarily — and this is an important message. Many patients with diabetic nephropathy who are identified at Stage 1 or Stage 2 and managed intensively never reach kidney failure in their lifetime. The risk of progression is significantly reduced with intensive glucose control, SGLT2 inhibitors, ACE inhibitors, and blood pressure management. Even patients at Stage 3 or Stage 4 can have progression slowed substantially. The patients who reach dialysis are more often those where nephropathy was not detected early, where risk factor control was suboptimal, or where progression was rapid from a severe initial glomerular injury pattern. Early detection and consistent treatment are the most effective strategies to avoid dialysis.
KIMS Secunderabad — Featuring a DM Nephrology-qualified nephrologist team, systematic microalbuminuria and eGFR screening protocol, evidence-based SGLT2 inhibitor and ACE inhibitor combination therapy, fistula-first planning at Stage 4, and 1,500+ kidney transplants for end-stage diabetic nephropathy. We offer continuity of care from early CKD to dialysis to transplant. NABH and NABL accredited, and Aarogyasri, CGHS, and EHS empanelled for dialysis and transplant.